Abstract
The development of gene-inactivation systems is an active and important field for both functional genomics and gene therapy. Towards this end, ribozymes (i.e. RNA enzymes), that specifically recognize and subsequently catalyze the cleavage of other target RNA molecules, are attractive molecular tools. Ribozymes represent an interesting alternative to the RNA interference (RNAi) approach for gene inactivation, especially given the fact that RNAi seems to trigger an immunological response and has demonstrated off-target effects. However, the design and optimization of a ribozymebased gene-inactivation system is not a straightforward procedure. Several aspects need to be considered in the experimental design in order to provide a suitable suppression system. In this review we present the advances in this domain made available from work using the hepatitis delta virus (HDV) ribozyme as a cis-acting RNA motif in molecular biology, as well as a trans-acting molecular scissor for the development of a gene-inactivation system. This HDV ribozyme technology possesses several unique features that are all related to the fact that it is the only catalytic cleaving RNA motif that has been discovered in humans.
Keywords: HDV ribozyme, RNA interference, antisense, ribozyme, deoxyribozyme, RNase P, functional genomic, gene therapy
Current Gene Therapy
Title: Development of Ribozyme-Based Gene-Inactivations; The Example of the Hepatitis Delta Virus Ribozyme
Volume: 7 Issue: 3
Author(s): M. Asif-Ullah, Michel Levesque, Gilles Robichaud and Jean-Pierre Perreault
Affiliation:
Keywords: HDV ribozyme, RNA interference, antisense, ribozyme, deoxyribozyme, RNase P, functional genomic, gene therapy
Abstract: The development of gene-inactivation systems is an active and important field for both functional genomics and gene therapy. Towards this end, ribozymes (i.e. RNA enzymes), that specifically recognize and subsequently catalyze the cleavage of other target RNA molecules, are attractive molecular tools. Ribozymes represent an interesting alternative to the RNA interference (RNAi) approach for gene inactivation, especially given the fact that RNAi seems to trigger an immunological response and has demonstrated off-target effects. However, the design and optimization of a ribozymebased gene-inactivation system is not a straightforward procedure. Several aspects need to be considered in the experimental design in order to provide a suitable suppression system. In this review we present the advances in this domain made available from work using the hepatitis delta virus (HDV) ribozyme as a cis-acting RNA motif in molecular biology, as well as a trans-acting molecular scissor for the development of a gene-inactivation system. This HDV ribozyme technology possesses several unique features that are all related to the fact that it is the only catalytic cleaving RNA motif that has been discovered in humans.
Export Options
About this article
Cite this article as:
Asif-Ullah M., Levesque Michel, Robichaud Gilles and Perreault Jean-Pierre, Development of Ribozyme-Based Gene-Inactivations; The Example of the Hepatitis Delta Virus Ribozyme, Current Gene Therapy 2007; 7 (3) . https://dx.doi.org/10.2174/156652307780859008
DOI https://dx.doi.org/10.2174/156652307780859008 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Lung Cancer May Increase Serum Procalcitonin Level
Infectious Disorders - Drug Targets Targeting the Arrhythmogenic Substrate in Atrial Fibrillation: Focus on Structural Remodeling
Current Drug Targets Biodiversity and Chemodiversity: Future Perspectives in Bioprospecting
Current Drug Targets Endocannabinoids in Appetite Control and the Treatment of Obesity
CNS & Neurological Disorders - Drug Targets MR Imaging of Pancreatic Islets: Tracking Isolation, Transplantation and Function
Current Pharmaceutical Design Adipocyte Fatty Acid Binding Protein (A-FABP) as a Potential New Therapeutic Target for the Treatment of Obesity - Associated Cancers
Current Drug Targets Treatment of HCV-Related Mixed Cryoglobulinemia
Current Drug Targets Anti-cancer Drug Discovery: Update and Comparisons in Yeast, Drosophila, and Zebrafish
Current Molecular Pharmacology Epigenetic Modifications Due to Heavy Metals Exposure in Children Living in Polluted Areas
Current Genomics Targeting Leptin as a Therapeutic Strategy against Ovarian Cancer Peritoneal Metastasis
Anti-Cancer Agents in Medicinal Chemistry Effects of Exercise on Anxiety and Depression Disorders: Review of Meta- Analyses and Neurobiological Mechanisms
CNS & Neurological Disorders - Drug Targets Bisphosphonates in Lung Cancer: Can They Provide Benefits Beyond Prevention of Skeletal Morbidity?
Anti-Cancer Agents in Medicinal Chemistry Epigenetic Alterations of the Wnt/β -Catenin Pathway in Human Disease
Endocrine, Metabolic & Immune Disorders - Drug Targets Chemotherapy and Targeted Agents for Elderly Women with Advanced Breast Cancer
Recent Patents on Anti-Cancer Drug Discovery Subject Index To Volume 6
Current Gene Therapy Role of Pancreatic β-Cell Death and Cell Death-Associated Inflammation in Diabetes
Current Molecular Medicine Patent Selections:
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Doing the Puzzle of Steroid Hormone Action: Biological Functions, Physiological and Clinical Significance of Plasma Membrane-Residing Glucocorticoid Recognizing Proteins
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Translating the Potential of Stem Cells for Diabetes Mellitus: Challenges and Opportunities
Current Stem Cell Research & Therapy Food-derived Bioactive Peptides - Opportunities for Designing Future Foods
Current Pharmaceutical Design